Q1 2026 · 13F-HR
RA CAPITAL MANAGEMENT, L.P.holdings as filed
Filed 2026-05-15 · accession 0001104659-26-062637
$9.44B
Reported value
85
Positions
2026-03-31
Period end
The Brief · RA CAPITAL MANAGEMENT, L.P. · Q1 2026
AI · grounded in 13F
RA CAPITAL MANAGEMENT, L.P. closed its position in CDTX for a reduction of $743.4M. The fund also exited positions in RNAGBP and ACLXGBX, reducing exposure by $623.3M and $82.6M respectively. On the buy side, the fund established a new position in SGP worth $207.8M and added ZLAB with a $107.4M investment. Additionally, the fund increased its share count in DNTH by 62.0%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S - ADR | $2.35B | 24.9% | 10,281,496 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $666.8M | 7.07% | 11,474,599 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $579.8M | 6.14% | 6,666,837 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $467.2M | 4.95% | 12,198,625 | Common | SOLE |
| 829401108 | SION | SIONNA THERAPEUTICS INC | $397.1M | 4.21% | 9,905,045 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $328.5M | 3.48% | 10,428,437 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA CO NV | $305.7M | 3.24% | 9,550,191 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC-A | $259.6M | 2.75% | 2,534,145 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $219.2M | 2.32% | 2,611,733 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $208.4M | 2.21% | 7,692,750 | Common | SOLE |
| 85220G109 | SGP | SPYGLASS PHARMA INC | $207.8M | 2.20% | 8,021,117 | Common | SOLE |
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $195.6M | 2.07% | 26,975,505 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $168.1M | 1.78% | 6,995,858 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $156.7M | 1.66% | 2,450,221 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $155.5M | 1.65% | 11,189,693 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $150.7M | 1.60% | 15,827,186 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS INC | $144.3M | 1.53% | 7,255,993 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $120.4M | 1.28% | 373,787 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $107.9M | 1.14% | 7,676,697 | Common | SOLE |
| 98887Q104 | ZLAB | ZAI LAB LTD-ADR | $107.4M | 1.14% | 5,707,262 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $105.3M | 1.12% | 23,555,648 | Common | SOLE |
| 929033207 | VOR | VOR BIOPHARMA INC | $96.4M | 1.02% | 5,404,998 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $95.0M | 1.01% | 63,771,366 | Common | SOLE |
| 82835W108 | SPRY | ARS PHARMACEUTICALS INC | $87.2M | 0.92% | 10,860,977 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $84.9M | 0.90% | 3,902,596 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $81.8M | 0.87% | 1,621,620 | Common | SOLE |
| 30054Y107 | EVMN | EVOMMUNE INC | $80.3M | 0.85% | 3,494,638 | Common | SOLE |
| 28658R106 | CLYM | CLIMB BIO INC | $77.4M | 0.82% | 11,300,939 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $67.2M | 0.71% | 9,339,978 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $63.5M | 0.67% | 9,853,302 | Common | SOLE |
| 36322Q206 | DMRA | DAMORA THERAPEUTICS INC | $62.1M | 0.66% | 2,399,310 | Common | SOLE |
| 98401F105 | XNCR | XENCOR INC | $59.1M | 0.63% | 4,897,237 | Common | SOLE |
| 50180M108 | LBRX | LB PHARMACEUTICALS INC | $54.5M | 0.58% | 2,208,604 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $51.6M | 0.55% | 3,671,083 | Common | SOLE |
| 00509G209 | ABOS | ACUMEN PHARMACEUTICALS INC | $49.5M | 0.52% | 20,992,669 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $47.0M | 0.50% | 5,049,779 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $46.4M | 0.49% | 6,053,960 | Common | SOLE |
| 14070B309 | CAPR | CAPRICOR THERAPEUTICS INC | $45.8M | 0.49% | 1,507,844 | Common | SOLE |
| 15673T100 | IPSC | CENTURY THERAPEUTICS INC | $40.1M | 0.43% | 17,754,430 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $38.8M | 0.41% | 2,600,000 | Common | SOLE |
| 52635N103 | LENZ | LENZ THERAPEUTICS INC | $38.2M | 0.41% | 4,178,823 | Common | SOLE |
| 61023L207 | MNPR | MONOPAR THERAPEUTICS INC | $36.6M | 0.39% | 667,207 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $35.5M | 0.38% | 20,064,545 | Common | SOLE |
| 25056L103 | DSGN | DESIGN THERAPEUTICS INC | $31.6M | 0.34% | 2,972,973 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $29.4M | 0.31% | 318,554 | Common | SOLE |
| 09077V100 | BIOA | BIOAGE LABS INC | $28.9M | 0.31% | 1,650,648 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $28.7M | 0.30% | 5,000,000 | Common | SOLE |
| 045396207 | ASMB | ASSEMBLY BIOSCIENCES INC | $28.3M | 0.30% | 1,020,410 | Common | SOLE |
| 76200L309 | RZLT | REZOLUTE INC | $28.0M | 0.30% | 9,180,000 | Common | SOLE |
| 01021M104 | AKTS | AKTIS ONCOLOGY INC | $26.9M | 0.28% | 1,503,084 | Common | SOLE |
| 00166B105 | ALXO | ALX ONCOLOGY HOLDINGS INC | $26.1M | 0.28% | 13,011,849 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $25.5M | 0.27% | 6,804,072 | Common | SOLE |
| 690469101 | OVID | OVID THERAPEUTICS INC | $23.8M | 0.25% | 10,714,000 | Common | SOLE |
| 65487U108 | NKTX | NKARTA INC | $22.8M | 0.24% | 10,805,129 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $22.2M | 0.24% | 746,841 | Common | SOLE |
| 384747101 | GRAL | GRAIL INC | $22.1M | 0.23% | 428,266 | Common | SOLE |
| 12529R107 | CCCC | C4 THERAPEUTICS INC | $21.0M | 0.22% | 8,000,000 | Common | SOLE |
| 75955J402 | RLMD | RELMADA THERAPEUTICS INC | $20.5M | 0.22% | 2,947,369 | Common | SOLE |
| 08205P209 | BNTC | BENITEC BIOPHARMA INC | $19.7M | 0.21% | 1,850,000 | Common | SOLE |
| 10919W405 | DRUG | BRIGHT MINDS BIOSCIENCES INC | $19.3M | 0.20% | 265,000 | Common | SOLE |
| 869367201 | STRO | SUTRO BIOPHARMA INC | $17.8M | 0.19% | 715,307 | Common | SOLE |
| 21217B100 | CTNM | CONTINEUM THERAPEUTICS INC-A | $16.9M | 0.18% | 1,296,012 | Common | SOLE |
| 78397T202 | SABS | SAB BIOTHERAPEUTICS INC | $16.9M | 0.18% | 4,401,500 | Common | SOLE |
| 457730109 | INSP | INSPIRE MEDICAL SYSTEMS INC | $16.8M | 0.18% | 325,663 | Common | SOLE |
| 03675P102 | AVR | ANTERIS TECHNOLOGIES GLOBAL | $16.6M | 0.18% | 3,000,000 | Common | SOLE |
| 68277Q105 | OKUR | ONKURE THERAPEUTICS INC-A | $16.6M | 0.18% | 3,998,333 | Common | SOLE |
| 433313103 | HNGE | HINGE HEALTH INC-A | $14.1M | 0.15% | 364,613 | Common | SOLE |
| 81663L200 | WGS | GENEDX HOLDINGS CORP | $13.5M | 0.14% | 209,887 | Common | SOLE |
| 946784105 | WAY | WAYSTAR HOLDING CORP | $12.8M | 0.14% | 529,400 | Common | SOLE |
| G4444S107 | HLXC | HELIX ACQUISITION CORP-CL A | $12.7M | 0.13% | 1,250,000 | Common | SOLE |
| 696389402 | PALI | PALISADE BIO INC | $12.5M | 0.13% | 7,124,116 | Common | SOLE |
| 004890109 | ACRV | ACRIVON THERAPEUTICS INC | $11.6M | 0.12% | 8,340,508 | Common | SOLE |
| 04965N104 | RNA | ATRIUM THERAPEUTICS INC | $11.6M | 0.12% | 864,102 | Common | SOLE |
| 48576U205 | KPTI | KARYOPHARM THERAPEUTICS INC | $10.7M | 0.11% | 1,917,354 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $9.9M | 0.10% | 662,968 | Common | SOLE |
| G70077105 | PCSC | PERCEPTIVE CAPITAL SOLUTIONS | $8.2M | 0.09% | 750,000 | Common | SOLE |
| 007002207 | ACET | ADICET BIO INC | $8.1M | 0.09% | 1,182,624 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA CO NV-27 | $6.7M | 0.07% | 333,333 | Common | SOLE |
| 221015100 | CRVS | CORVUS PHARMACEUTICALS INC | $6.6M | 0.07% | 450,000 | Common | SOLE |
| 753018100 | RANI | RANI THERAPEUTICS HOLDINGS-A | $6.2M | 0.07% | 8,500,000 | Common | SOLE |
| 29446K106 | EQ | EQUILLIUM INC | $6.2M | 0.07% | 3,096,336 | Common | SOLE |
| 95075A107 | HOWL | WEREWOLF THERAPEUTICS INC | $5.6M | 0.06% | 6,681,307 | Common | SOLE |
| 556099109 | MGNX | MACROGENICS INC | $5.4M | 0.06% | 1,864,176 | Common | SOLE |
| 56565P103 | MPLT | MAPLIGHT THERAPEUTICS INC | $5.0M | 0.05% | 248,294 | Common | SOLE |
| 696077601 | PTN | PALATIN TECHNOLOGIES INC | $1.2M | 0.01% | 70,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.